Blog

Efinopegdutide (MK‑6024): Dual GLP‑1/Glucagon Peptide for Metabolic Liver Disease

Efinopegdutide (MK‑6024) is a dual GLP‑1/glucagon receptor agonist under investigation for treating metabolic-associated fatty liver disease (MAFLD) and related metabolic disorders. Developed by Merck, this synthetic, PEGylated peptide is engineered to improve liver fat reduction, glucose control, and cardiometabolic health. While GLP‑1 agonists like semaglutide and liraglutide have transformed the treatment of obesity and type 2 […]